NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab [ID760]

Please sign and return via NICE Docs/Appraisals.

I confirm that:

- I agree with the content of the submission provided by **the NCRI/RCP/RCR/ACP** and consequently I will not be submitting a personal statement.

Name: .....[redacted]
.....

Signed: .....

Date: 09 07 15
.....